IMCR — Immunocore Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $5.66bn
- $5.26bn
- $249.43m
- 84
- 13
- 74
- 57
Annual cashflow statement for Immunocore Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2019 December 31st | C2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | -133 | -95 | -180 | -52.5 | -55.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -14.8 | -9.73 | 51.3 | 22.2 | 48.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.33 | 14.7 | -22 | -24.2 | 5.78 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -131 | -78.5 | -143 | -49.2 | 2.94 |
| Capital Expenditures | -5.46 | -3.94 | -1.39 | -2.2 | -5.42 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 2.12 | 5.41 | 0.106 | 0.006 | 0 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.33 | 1.47 | -1.28 | -2.2 | -5.42 |
| Financing Cash Flow Items | -0.942 | -0.226 | — | -1.77 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 70.3 | 149 | 288 | 145 | 34.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -64.3 | 71.5 | 144 | 81.4 | 40.2 |